MaxWell Biosystems

MaxWell Biosystems operates at the intersection of neuroscience research, biotechnology, and laboratory instrumentation. Its stated focus is enabling basic neuroscience research and preclinical drug discovery through high-density microelectrode array (HD-MEA) systems. The MaxOne system is described as having 26,400 electrodes, 1,024 low-noise readout channels, and 32 stimulation channels, while the product range also includes the multi-well MaxTwo platform and MaxLab Live analysis software. This combination puts the company in the functional cell-assay and electrophysiology tools segment, where researchers can measure cellular and network activity directly rather than relying only on indirect readouts. Website positioning emphasizes single-cell sensitivity alongside multi-well throughput, label-free observation, and long-term studies. Its stated points of differentiation are therefore best understood as technical and workflow attributes: dense electrode coverage, integrated stimulation and recording, multi-well formats, and automation-compatible research workflows. The company is private, has a reported employee range of 51–100, and has raised $4,728,542 across six recorded rounds, including a Series A led by Sensirion.

Founded in 2016, MaxWell Biosystems has progressed from early grants and pre-seed support into commercial electrophysiology instrumentation. Its recorded early financing includes grants in 2016, 2019, and 2019, plus a $99,096 pre-seed round led by Venture Kick in 2017. The largest disclosed round was a $4,517,064 Series A led by Sensirion on Dec 16, 2020. Product breadth has expanded beyond the single-well MaxOne system to include the MaxTwo multi-well platform and MaxLab Live software, with website information also describing six- and 24-well plates and a perfusion system. The Jun 30, 2025 opening of a San Diego subsidiary is a clear geographic inflection point, creating an Americas hub as the company pursues international growth. Hiring activity is indicated, although specific roles and employee-growth figures are unavailable. Taken together, the disclosed milestones show a shift from early research-stage funding toward a broader product offering and international commercial presence.